You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 9, 2026

Court Judgment Reaffirms Rules on Advertising of Medical Facilities in Thailand

On August 5, 2026, the Consumer Case Division of Thailand’s Civil Court rendered a judgment in a case involving a beauty clinic that advertised acne scar treatments using claims that the clinic was operated by a specialist physician and that the treatment, allegedly involving stem cell technology, could permanently remove acne scars.

The plaintiff brought a claim against both the physician-owner and the clinic company, alleging that the advertisements were false and induced her to purchase the treatment. The court found that the clinic was liable for the false representations and that the physician-owner, as both the authorized director of the company and the medical practitioner who provided treatment, was jointly responsible.

Although the plaintiff could not fully prove all damages claimed, the court awarded compensation of THB 20,000, together with interest.

While the judgment arose from a consumer protection dispute, it serves as a valuable reminder that medical facility advertisements in Thailand are regulated and may expose clinics and healthcare providers not only to regulatory enforcement but also to civil liability from patients who rely on misleading promotional claims.

Regulatory Framework Governing Medical Facility Advertisements

Medical facility advertising in Thailand is governed by the Medical Facility Act B.E. 2541 (1998), as amended by the Medical Facility Act (No. 4) B.E. 2559 (2016).

The principal secondary legislation is the Department of Health Service Support (DoHSS) Notification Re: Rules, Procedures, Conditions, and Fees for an Advertisement or Publication Concerning a Medical Facility, which came into force on November 25, 2019. Under this notification, “advertising” includes any act, by any means, that causes members of the public to see, hear, or otherwise become aware of a message, sound, or image for the commercial benefit of a medical facility. This broad definition covers not only traditional media but also clinic websites, social media, and other digital marketing channels.

Prior Approval Requirement

Section 38 of the Medical Facility Act requires medical facilities to obtain approval from the DoHSS before publishing any advertisement relating to the facility.

The only statutory exception is where the communication contains solely the medical facility’s name and location exactly as stated in its license.

Section 38 also expressly prohibits advertisements containing false, exaggerated, deceptive, or misleading statements—regarding the medical facility’s name or location, the medical services offered, the qualifications of healthcare professionals, or the competence or capabilities of healthcare personnel—that are intended to induce individuals to use the facility’s services.

The recent acne scar treatment case demonstrates the risk associated with claims that promise specific results, represent a doctor as possessing special expertise without adequate substantiation, or suggest that a treatment can permanently cure a condition.

Advertisements Exempt from Prior Approval

The 2019 notification permits certain information to be displayed within the medical facility premises without obtaining prior approval, including:

  • Abbreviations, trade names, logos, and symbols
  • Qualifications of healthcare professionals
  • Service fees and pricing information
  • Patient rights information
  • Lists of medical services and operating hours
  • Medical and public health knowledge, research findings, and educational content (subject to prescribed warning statements)
  • Announcements concerning facility activities, relocation, destruction of records, or commemorative events

Advertisements That May Be Approved

Advertisements outside the exemption categories require approval before publication. The DoHSS may approve advertisements that contain the following promotional elements, provided specific conditions are met:

  • Free medical services. Advertisements promoting free services must clearly state the date and time, the location, and the scope of the services offered.
  • Gifts, exchanges, benefits, prizes, or lucky draws. These may be offered only if the service recipient is the direct beneficiary and the medical service provided is not below the general standard.
  • Discounts on non-medical services. These may be offered only if the service recipient is the direct beneficiary.
  • Discounts on medical services. These may be offered for a period of up to one year.

Application Procedures

The approval process depends on the location of the medical facility.

  • For facilities located in Bangkok, applications must be submitted to the Center of Healthcare Advertising Approval (CHAA) within the DoHSS. Applications may be filed in person or by post. According to the CHAA website, straightforward applications involving text or still images may be approved within approximately five to seven working days after complete documentation is submitted.
  • For facilities located outside Bangkok, applications must be submitted to the relevant Provincial Public Health Office.

Penalties for Noncompliance

Failure to obtain prior approval may result in a fine of up to THB 20,000 and an additional daily fine of up to THB 10,000 for failure to comply with an order requiring the advertisement to be removed.

Advertisements that are false, exaggerated, deceptive, or misleading carry more severe penalties: imprisonment of up to one year, a fine of up to THB 20,000, or both. Additional daily fines of up to THB 10,000 may also be imposed until the offending advertisement is withdrawn.

Increased Enforcement Against Repeat Offenders

According to recent statements from the DoHSS, enforcement against repeat offenders is becoming increasingly stringent. The department reportedly applies an escalating penalty approach:

  • First violation: approximately 25 percent of the maximum fine
  • Second violation: approximately 50 percent
  • Third violation: approximately 75 percent
  • Fourth violation: referral for criminal prosecution

Importantly, the authority currently considers each advertising platform separately. In other words, violations are generally assessed by channel rather than by the number of individual posts. However, authorities have indicated that future enforcement may consider each prohibited claim separately, potentially increasing exposure significantly, including the risk that serious or repeated violations may give rise not only to civil claims but also to criminal complaints or prosecution.

The DoHSS is also reportedly considering introducing informer reward mechanisms for advertising violations, although the proposal remains under review. If adopted, such mechanisms could further increase the likelihood of complaints being filed, including potential criminal complaints in cases involving false, exaggerated, deceptive, or misleading advertising.

As enforcement activity continues to increase, the distinction between aggressive marketing and unlawful advertising is becoming increasingly important. A misleading claim may not only result in regulatory penalties but may also expose the clinic, its directors, and treating healthcare professionals to civil claims from dissatisfied patients and, where the facts support it, to criminal complaints or prosecution under the applicable statutory framework.

RELATED INSIGHTS​ 

August 29, 2023
Since the June 9, 2022, delisting of all parts of the cannabis plant according to the Narcotics Code, there has been an explosion of cannabis dispensaries operating in Thailand. The Department of Thai Traditional and Alternative Medicine (DTTAM) has issued more than 12,000 cannabis dispensary licenses to businesses in Thailand. A license allows a dispensary to sell cannabis flowers legally. In addition, the DTTAM requests the cooperation of dispensaries in submitting monthly reports about the sourcing, selling, and inventory of cannabis flowers. The DTTAM may suspend the selling license of dispensaries that fail to submit these reports. Apart from the enforcement duties and administrative acts of the DTTAM, the enactment of the laws and regulations pertaining to cannabis seemed to be drastically winding down. One of the reasons was that Thailand had delays in the process of forming a new government following the general election of May 14, 2023. These delays dampened Thailand’s thriving cannabis industry. In particular, the industry has concerns about the uncertainty of the nascent cannabis law. On August 11, 2023, the Narcotics Control Division of the Thai Food and Drug Administration (FDA) posted the Draft Regulation Re: Application for Approval and Approval for Manufacture, Importation, Exportation, Distribution or Possession of Narcotics under Category 5 (Extracts from Cannabis or Hemp Plants Only). This may be the first regulation that the newly formed government implements with regard to cannabis extracts. Unlike the DTTAM’s enforcement activities, the Thai FDA requests that a domestic manufacturer, importer, exporter, or seller of cannabis extracts apply for a license. The Thai FDA, as the authority, will consider granting a license only in the following cases: For medical benefits; For commercial or industrial benefits; For the benefit of medical or scientific analysis or research; and For use by the government for preventing and
July 11, 2023
Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning
July 10, 2023
One of the more positive outcomes of the COVID-19 pandemic is that telemedicine has become remarkably important as an interactive system between patients and healthcare professionals. Thailand, which ranks near the top as a world medical hub, is a highly favored destination in Asia for expat workers. Currently, the Thai market has both Thai-based and foreign-based platforms with information about healthcare providers and telemedicine readily available. “Doctor Locator,” “Weed Map,” and “Find a Teeth Aligner Dentist” are examples of online platforms connecting patients with medical and telemedicine services. These digital platforms provide information about the location of specialized clinics, cannabis dispensaries, pharmacy stores, and orthodontic practitioners in Thailand. These platforms act as intermediaries between medical care businesses and consumers. As actual medical services are not offered or provided, these digital platforms do not have to be regulated under the Medical Facility Act of Thailand. However, healthcare digital platform services that act as an intermediary or conduit managing information used to connect medical clinics or cannabis dispensaries with patients or customers via a computer network are now regulated under the soon-to-be-implemented Royal Decree on Digital Platforms, regardless of whether payment is actually made via the platform. The regulatory authority for this is the Electronic Transactions Development Agency (ETDA). Under this royal decree, digital platform providers that intend to operate a digital platform service must notify the ETDA prior to initiating operations. The extent of the details to be included in the notification to the ETDA will be more comprehensive if the digital platform: has annual revenue (before expenses) for digital platform services within Thailand exceeding THB 1.8 million (approx. USD 51,200) for an individual operator or THB 50 million (approx. USD 1.42 million) for a corporate or entity operator; or has more than 5,000 users (on average) per month. Apart
July 10, 2023
On June 30, 2023, the Ministry of Health of Vietnam issued Circular No. 14/2023/TT-BYT stipulating the process and procedure for building bidding package prices for procurement of goods and services in the field of medical devices at public health facilities (“Circular 14”). Circular 14 took effect on July 1, 2023, and will be valid through the end of 2023. Circular 14 applies to the procurement of medical devices/equipment and their accessories, spare parts, and supplies, as well as related services of repair, maintenance, inspection, and calibration. Under Circular 14, there are three methods of determining the price of bidding packages: Collecting quotations provided by suppliers of goods and services in the field of medical devices. Surveying the winning bid prices of similar goods and services on the national bidding network system (https://muasamcong.gov.vn). Using the results of price appraisal of a competent state agency that conducts price appraisal, or a specialized price appraisal enterprise. Method (i) must be used first; the two remaining methods can be applied only after method (i) has been unsuccessful. If the investor/procuring entity uses two or more methods to determine the price of bidding packages, it can select the highest price that is suitable to its financial capacity and professional requirements. Circular 14 further sets out the specific step-by-step process to build prices for procuring products and services in the field of medical devices/equipment. Transitional Provision For bidding packages that have already approved a contractor selection plan before July 1, 2023, the approved contractor selection plan will be followed. For bidding packages for which a contractor selection plan has been submitted by the investor/procuring entity but the plan has not yet been approved, the competent person can decide on the approval of the submitted plan or can request the investor/procuring entity to rebuild the bidding